• "Covid-19 drugs and vaccines: big money and winning alliances" (June 2021) > HERE
   
• "Waste in covid-19 clinical trials" (June 2021) > HERE
    
• "Covid-19 vaccine Ad26.CoV2S (by Janssen): as with the other covid-19 vaccines, effective in the short term but unknowns remain" (23 March 2021) > HERE
   
• "The AstraZeneca covid-19 vaccine: British epidemiological data on the vaccination of older adults, and reassuring pharmacovigilance data" (15 March 2021) > HERE
  
  
• "Messenger RNA covid-19 vaccines: Prescrire's in-depth analysis as of end February 2021 (2 March 2021) > HERE
  
  
• "Covid-19 and ivermectin: many trials, few results, no proven efficacy " (13 February 2021) > HERE
  
  
• "The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy" (29 January 2021) > HERE
  
  
• "The covid-19 messenger RNA vaccine from Moderna: as with the tozinameran vaccine (Comirnaty°, Pfizer/BioNTech), limited data and unanswered questions" (6 January 2021) > HERE
   
• "The covid-19 messenger RNA vaccine tozinameran (Comirnaty°, from Pfizer and BioNTech) in elderly patients: limited data, many uncertainties" (23 December 2020) > HERE
   
• "Covid-19 and vitamin D: too uncertain" (15 December 2020) > HERE
   
• "Evaluation of covid-19 vaccines: the questions to ask" (20 November 2020) > HERE
   
• "Covid-19 patients who are not hospitalised: anticoagulation is rarely justified" (24 September 2020) > HERE
   
  
• "Proton pump inhibitors: increased risk of severe covid-19" (15 September 2020) > HERE
   
• "Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease" (24 July 2020) > HERE
   
• "Covid-19: remdesivir (Veklury°) authorised in the European Union, yet much remains unknown or uncertain" (13 July 2020) > HERE
   
• "Covid-19 and severe breathing problems: dexamethasone reduced mortality in one trial" (24 June 2020) > HERE
   
• "Lack of access to drug evaluation data: a recurrent problem, not confined to covid-19" (8 June 2020) > HERE
   
• "Covid-19 and  hydroxychloroquine  (Plaquenil°): new data  show no evidence of efficacy"  (16 April 2020) > HERE
   
• "New data on the  cardiac adverse effects  of the combination of  hydroxychloroquine  (Plaquenil°) with azithromycin (Zithromax° or other brands)" (16 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine (Plaquenil°): still no conclusive results" (15 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine: uncertainties and unanswered questions" (2 April 2020) > HERE
  
  
• "Covid-19 and hydroxychloroquine: caution" (30 March 2020) > HERE
   
• "Covid-19 and drug trials: what to make of the initial results?" (23 March 2020) > HERE
  
  
• For more information in French, see www.prescrire.org > Dans l'actualité
  

©Prescrire July 2021

For more updates, follow us on Facebook and Twitter

Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. > Follow us on Facebook or > Follow us on Twitter